Silexion Therapeutics Corp 正式通报,截至2026年7月29日,该公司已成功获得在以色列开展Sil204试验所需的所有监管批准。这一里程碑式的进展,标志着其研发管线向前迈出了关键一步。
Silexion Therapeutics Corp 正式通报,截至2026年7月29日,该公司已成功获得在以色列开展Sil204试验所需的所有监管批准。这一里程碑式的进展,标志着其研发管线向前迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.